Clinical experience with everolimus (Certican) in elderly recipients: The "old-for-old" concept

Transplantation

Volumn 79, Issue 9 SUPPL., 2005, Pages

  Pascual, Julio ^a   Marcén, Roberto ^a   Ortuño, Joaquín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cyclosporine; Elderly; Everolimus; Renal transplantation

Indexed keywords

ATORVASTATIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; NIFEDIPINE; PREDNISONE; VERAPAMIL;

AGED; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DONOR; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN;

AGE FACTORS; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; SIROLIMUS;

EID: 18544375167     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000162431.96893.AE     Document Type: Article

References (12)

1. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
2. Pascher A, Pratschke J, Neuhaus P, Tullius SG. Modifications of immune regulations with increasing donor & recipient age. Ann Transplant 2004; 9: 72.
3. Pascual J, Marcen R, Liano F, Ortuno J. Cadaveric kidney transplantation for the elderly. Nephron 2002; 91: 361.
4. Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004; 19(Suppl 3): 11.
5. Kruger B, Zulke C, Fischereder M, et al. Early experience with the ET Senior Program "Old For Old"; better to be number one? Transpl Int 2002; 15: 541.
6. Morrissey PE, Gohh R, Yango A, et al. Renal transplant survival from older donors: a single center experience. Arch Surg 2004; 139: 384.
7. Cohen B, Smits JM, Haase B, et al. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant 2005; 20: 34.
8. Smits JM, Persijn GG, van Houwelingen HC, et al. Evaluation of the Eurotransplant Senior Program. The results of the first year. Am J Transplant 2002; 2: 664.
9. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
10. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
11. Ruiz JC, Campistol JM, Grinyo JM, et al. Early cyclosporine A withdrawal in kidney transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004; 78: 1312.
12. Nashan B. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors. Transpl Int 2004; 17: 279.